CYDY - FDA resumes eIND approval for use of leronlimab in COVID-19

CytoDyn (CYDY) announces that a treating physician has received authorization from the FDA to administer leronlimab for a COVID-19 patient under emergency IND (eIND). In recent months, leronlimab has received more than 60 eIND authorizations from the FDA.FDA’s decision will enable the company to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded.CytoDyn has completed enrollment in its Phase 3 trial.Leronlimab has become a debate topic over its ability to help COVID-19 patients, or even become a "cure" for this terrible pandemic.CYDY has rallied around 63% over the past six months.

For further details see:

FDA resumes eIND approval for use of leronlimab in COVID-19